We have developed a homogeneous substrate-labeled fluorescent immunoassay for the measurement of dibekacin concentrations in serum and plasma. The fluorogenic enzyme substrate ,B-galactosyl-umbelUiferone was covalently attached to tobramycin, an aminoglycoside structurally similar to dibekacin, to prepare a fluorogenic drug reagent (FDR). The FDR is nonfluorescent under assay conditions, but fluoresces upon hydrolysis by P-galactosidase. However, binding of the FDR by antiserum to the cross-reactive drug kanamycin prevents enzyme hydrolysis. The fixed level of FDR competes with dibekacin within the sample for the limiting number of antibody-binding sites in the reaction mixture. Unbound FDR is hydrolyzed by ,B-galactosidase to release a fluorescent product that is proportional to the dibekacin concentration in the sample. The assay exhibits good precision, standard curve reproducibility, recovery, sensitivity, and correlation with a comparative method. Additionally, the substrate-labeled fluorescent immunoassay is rapid and easy to perform. Dibekacin (3',4'-dideoxykanamycin B) is a semisynthetic aminoglycoside antibiotic useful in the treatment of severe gram-negative bacterial infections (6, 9, 10). Since dibekacin has a rather narrow therapeutic range and may be ototoxic or nephrotoxic at high concentrations in the blood, therapeutic drug monitoring is indicated (3, 4, 7, 8 
We have developed a homogeneous substrate-labeled fluorescent immunoassay for the measurement of dibekacin concentrations in serum and plasma. The fluorogenic enzyme substrate ,B-galactosyl-umbelUiferone was covalently attached to tobramycin, an aminoglycoside structurally similar to dibekacin, to prepare a fluorogenic drug reagent (FDR). The FDR is nonfluorescent under assay conditions, but fluoresces upon hydrolysis by P-galactosidase. However, binding of the FDR by antiserum to the cross-reactive drug kanamycin prevents enzyme hydrolysis. The fixed level of FDR competes with dibekacin within the sample for the limiting number of antibody-binding sites in the reaction mixture. Unbound FDR is hydrolyzed by ,B-galactosidase to release a fluorescent product that is proportional to the dibekacin concentration in the sample. The assay exhibits good precision, standard curve reproducibility, recovery, sensitivity, and correlation with a comparative method. Additionally, the substrate-labeled fluorescent immunoassay is rapid and easy to perform. Dibekacin (3',4'-dideoxykanamycin B) is a semisynthetic aminoglycoside antibiotic useful in the treatment of severe gram-negative bacterial infections (6, 9, 10) . Since dibekacin has a rather narrow therapeutic range and may be ototoxic or nephrotoxic at high concentrations in the blood, therapeutic drug monitoring is indicated (3, 4, 7, 8 Gentamicin, amikacin, and tobramycin were obtained from U.S. Pharmacopeial Convention, Inc., Rockville, Md., dibekacin was obtained from Meiji Seika Kaisha, Ltd., Tokyo, Japan, and kanamycin was purchased from Bristol Laboratories, Syracuse, N.Y. The structural similarity of the related aminoglycosides dibekacin, kanamycin, and tobramycin is shown in Fig. 1 FDR. The FDR 3-galactosyl-umbelliferone-tobramycin was synthesized as described previously (1) .
Antiserum. Antiserum to kanamycin was produced in goats with a kanamycin-bovine serum albumin conjugate (5) .
SLFIA for the determination of dibekacin levels in serum. The SLFIA was performed using a semiautomated procedure. Fig. 2 . The addition of Competitive binding reactions. The effect of various incubation times on the dibekacin standard curve was followed (Fig. 3) . The curves in Fig. 3A show the measured fluorescence, whereas the curves in Fig. 3B are normalized to the fluorescence of the high standard. Although the dibekacin assay is normally run with a 20-min incubation, it is possible to incubate the reactions for alternative lengths of time, depending on the requirements of the user. Shorter incubation times enable one to obtain results quickly but limit the number of samples that can be processed per run. Longer incubation times enable one to assay a larger number of samples in a run. Acceptable standard curves were generated with incubation times offrom 5 to 60 min. The fluorescent response of the assay (the difference in fluorescence between the 0-and 16-p,g/ml standards) increased from 3.3 relative fluorescence units at 5 min to 7.4 at 60 min.
Performance characteristics of the dibekacin SLFIA. The intraassay precision of the dibekacin SLFIA was evaluated by assaying 1 dilution of each of the dibekacin controls (2, 6, and 14 p,g/ml) 20 times and also 20 dilutions of each control once (Table 1) . Each standard was assayed in duplicate. Interassay precision was determined from data generated in 10 runs over a period of 8 days. In each run, five dilutions of each control were assayed once ( Table 2 ). Precision over the 10 runs was good. The assay was very reproducible over the 8-day period (Fig. 4) .
Recovery experiments were performed by diluting a 20-,ug/ml contrived dibekacin serum sample 1:1 with 50 mM Bicine-0.1% azide, pH 8.3. The recovery of the diluted sample was 100.6% of the expected value. The dibekacin concentrations of clinical samples determined by SLFIA were compared with those measured by HPLC (Fig. 5) . Comparison of the two methods revealed both good correlation (r = 0.987) and regression parameters.
Specificity of the dibekacin SLFIA. The crossreactivity of the antiserum to kanamycin for dibekacin and other aminoglycosides was examined by measuring the dose response of various aminoglycosides in the dibekacin assay (Fig. 6) the antiserum was produced in response to a kanamycin immunogen, dibekacin was the most reactive, whereas tobramycin and kanamycin, both structurally very similar to dibekacin, cross-reacted 94 and 69o, respectively. Amikacm cross-reacted 1%, whereas the unrelated aminoglycoside gentamicin did not cross-react at all. Other antibiotics that may be coadministered with dibekacin, such as carbenicillin, cephalothin, chloramphenicol, erythromycin, methicillin, neomycin, and tetracycline, did not cross-react or interfere in the assay when therapeutic levels were assayed in the presence of dibekacin. Sensitivity of the dibekacin SLFIA. The sensitivity of the dibekacin SLFIA was evaluated by assaying five replicates each of the -,ug/ml standard and 0.8-, 1.6-, 2.4-, and 3.2-ixg/ml standards which were contrived by diluting the 4-,g/ml standard with the 0-,ug/ml standard. This study indicated that 0.5 ,ug of dibekacin per ml could be distinguished from the 0-u.g/ml standard at a 95% confidence level.
DISCUSSION
The dibekacin SLFIA takes advantage of the cross-reactivity of dibekacin, tobramycin, and kanamycin for binding to an antiserum to kanamycin. The assay described herein is similar to the tobramycin SLFIA (1) in that both assays employ antiserum to kanamycin and 3-galactosyl-umbelliferone-tobramycin as the FDR. They differ, however, in the optimal concentrations of these reagents.
Various studies were carried out to establish the validity of the dibekacin SLFIA. This assay exhibited very good intra-and interassay precision, reproducibility of the standard curve, and recovery of the drug. Comparison of the SLFIA with HPLC values yielded good correlation, and the assay is sensitive to 0.5 ,ug/ml. The evaluation demonstrated that the dibekacin SLFIA is a rapid, Precise, and accurate assay.
